The new facility will primarily handle the blister packaging of Eisai's investigational treatment lenvatinib which is used to treat thyroid cancer as well as other types of solid tumors...Teva will now have access to Microdose's technology including its multidose dry powder nebulizer device...Stifel acted as exclusive financial advisor to Microdose in the transaction

The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous formulation of BMS' Orencia (abatacept), for the treatment of rheumatoid arthritis...Costs related to the reorganization are not expected to have a material effect on the group's finances

Elan continued to encourage shareholders not to tender shares in Royalty's current hostile bid for the biotech...According to Royalty, a "sufficient number of these ADSs" voted against Elan's proposed $1 billion cash acquisition of a royalty stream from South San Francisco-based Theravance Inc...related to its chronic obstructive pulmonary disease drug collaboration with London-based Glaxosmithkline plc, as well as Elan's proposed buyout of Vienna, Austria-based AOP Pharmaceuticals AG for €263.5

Astrazeneca will have first rights to the molecules discovered through the agreement and can choose further development in exchange for royalty payments to Cancer Research Technology...The second agreement allows Cancer Research UK scientists from the Paterson Institute to test a potential drug target against Astrazeneca's compound collection at Alderley Park to see if any could potentially work as a new drug

Breckenridge Pharmaceutical Inc., of Boca Raton, Fla., entered into a development agreement with Welding GmbH & Co., of Hamburg, Germany, and SK Chemicals, of Seoul, South Korea, to develop and market an undisclosed drug candidate with potential U.S.-branded sales of approximately $500 million...Fluzone Quadrivalent vaccine includes two A strains and two B strains to help protect against influenza disease

In addition to the research collaboration, which includes three cancer targets, Isis and AstraZeneca are developing two antisense drugs, ISIS-ARRx and ISIS-STAT3RX, discovered by Isis and licensed to AstraZeneca for the treatment of cancer. (See BioWorld Today, Dec. 12, 2012...The company expects to enter a third agreement (separation agreement) governing other terms of the firms' business relationship

Safyral is approved to prevent pregnancy in women who elect to use an oral contraceptive and to provide a daily dose of folate supplementation

Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., entered a distribution agreement with Tecnofarma International Ltd., of Buenos Ares, Argentina, to distribute enzalutamide (Xtandi in the U.S.) in Latin America, excluding Brazil, upon regulatory approvals in the various countries...Johnson & Johnson, of New Brunswick, N.J., said its Johnson & Johnson Innovation arm signed an agreement with the California Institute for Quantitative Biosciences (QB3) to allocate 5,000 square

Treatment was shown to significantly reverse the pulmonary hypertension associated with advanced stages of the disease and restore cardiovascular function...Under the terms, Genor licensed to Biocnd the South Asia, Southeast and Northeast Asia (except Greater China) and Russian rights to GB232, a biosimilar of Humira (adalimumab, AbbVie Inc.) and rest-of-world rights (except Greater China, Japan, the U.S. and Europe) to GB221 , a biosimilar of Herceptin (trastuzumab, Roche AG...The therapy is designed

according to the protocol, all patients were to have been treated with both bortezomib and lenalidomide prior to study entry...Based on the positive results GSK said it is planning to make regulatory submissions in Europe, the U.S., as well as other regions during the next few

to manufacture, market and sell six dermatology and three antiviral products from GSK...patients to continue to have access to treatments and allows the Stiefel U.S

Shire plc, of Dublin, settled litigation against Teva Pharmaceuticals USA Inc., a division of Teva Pharmaceutical Industries Ltd., of Jerusalem, related to Teva's abbreviated new drug application for a generic version of Shire's Intuniv (guanfacince) for attention deficit hyperactivity disorder...The settlement allows Teva a license to market its own generic versions of Intuniv or authorized versions of Intuniv provided by Shire

If approved, Lojuxta will be indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH...according to the protocol, all patients were to have been treated with both bortezomib and lenalidomide prior to study entry

and cancellation of all outstanding employee stock options and other agreements granting rights to subscribe for purchase any shares or other securities in Allon...Oramed is required to pay royalties in the rate of 3 percent to 5 percent on sales of products and services derived from the technology developed using this and other OCS grants until the full amount is repaid, plus interest

As of the end of April, 943 employees, or about 77 percent, have had their future employment status clarified, including 300 employees who accepted the offer of transfers to other Merck Serono sites, 43 people who were redeployed through the creation of seven start-up companies and 80 employees that accepted early retirement...Merck Serono decided last year to shutter its Geneva headquarters. (See BioWorld Today, June 20, 2012

In other news, Perrigo received approval for the generic version of Sanctura XR (trospium chloride; Allergan Inc.) to treat overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency

IBC Generium is granted an exclusive license for other territories, and also has the right to an exclusive license for Russia and CIS states...The company plans to reconstruct an operational plant by overhauling the expansion facility that was under construction...Scynexis said it plans to progress the clinical development while evaluating new partnership opportunities

Additional funding of up to €9 million is anticipated in the following three years...In other news, Elan priced its offering of $850 million aggregate principal amount of 6.25 percent senior notes due 2021 by its wholly owned subsidiaries, Elan Finance public limited co

In separate news, Valeant said it received a received a complete response letter from the FDA for its new drug application for efinaconazole to treat onychomycosis...Questions raised by the FDA pertain to chemistry, manufacturing and controls related to areas of the container closure apparatus